| ［1］Broxmeyer L.Bacteriophages: antibacterials with a future?［J］. Med Hypotheses,2004,62(6):889-893.［2］ Hatfull GF, Jacobs-Sera D, Lawrence JG, Pope WH, Russell DA, Ko CC, Weber RJ, Patel MC, Germane KL, Edgar RH, Hoyte NN, Bowman CA, Tantoco AT, Paladin EC, Myers MS, Smith AL, Grace MS, Pham TT, O’Brien MB, Vogelsberger AM, Hryckowian AJ, Wynalek JL, Donis-Keller H, Bogel MW, Peebles CL, Cresawn SG, Hendrix RW.Comparative genomic analysis of 60 Mycobacteriophage genomes: genome clustering, gene acquisition, and gene size［J］.mol biol, 2010,397(1):119-143.［3］ Lenski RE. Dynamics of interactions between bacteria and virulent bacteriophage［J］.Adv Microb Ecol,1988,10: 1-44.［4］ 吴雪琼,张宗德,乐军. 分枝杆菌分子生物学［M］.北京:人民军医出版社,2010:54-57.［5］ Chanishvill N, Chanishvili T,Tediashvili M. Phages and their application againstdrug-resistant bacteria［J ］. Journal of Chemical Technology and Biotechnology,2001,76:689-699.［6］ Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapyand antibacterials［J］. Trends Biotechnol, 2006,24(5):212-218.［7］ Bergval IL, Schuitema AR, Klatser PR, Anthony RM. Resistant mutants ofMycobacterium tuberculosisselectedin vitrodo not reflect thein vivomechanism of isoniazid resistance［J］. J Antimicrob Chemother, 2009,64(3):515-523.［8］ anerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, Nitta A, Royce S,FloodJ. Extensively drug-resistant tuberculosis in California 1993—2006［J］. Clin Infect Dis,2008,47(4):450-457.［9］ Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosisundertakenby the British Medical Research Council tuberculosis units, 1946—1986, with relevant subsequentpublications［J］. Int J Tuberc Lung Dis, 1999(10 Suppl2):S231-279. ［10］O’Brien RJ, Nunn PP.The need for new drugs against tuberculosis［J］.Am J Respir crit Care Med,2001,162: 1055-1058.［11］ Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculousmycobacterial disease prevalence and risk factors: a changing epidemiology［J］. Clin Infect Dis,2009,49(12):124-129. ［12］ Billinger ME, Olivier KN, Viboud C, de Oca RM, Steiner C, Holland SM, Prevots DR. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States,1998—2005［J］. Emerg Infect Dis, 2009,15(10):1562-1569.［13］ akarova MV, Freǐman GE. Study of the drug-sensitivity of nontuberculous mycobacteria［J］. Probl Tuberk Bolezn Legk,2009,7:55-58. ［14］ Ranjan A, Vidyarthi AS, Poddar R. Evaluation of codon bias perspectives in phage therapy ofMycobacterium tuberculosisby multivariate analysis［J］. In Silico Biol, 2007,7(4-5): 423-431. ［15］ Broxmeyer L, Sosnowska D, Miltner E, Chacón O, Wagner D, McGarvey J, Barletta RG, Bermudez LE. Killing of Mycobacterium avium andMycobacterium tuberculosisby a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens［J］. J Infect Dis, 2002,186(8):1155-1160.［16］ Danelishvili L, Young LS, Bermudez LE.In vivoefficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium［J］.Microb Drug Resis, 2006, 12(1):1-6.［17］ 黄新, 高飞絮,常胜合,秦广雍,方华圣.噬菌体脂质体包被液治疗小鼠耐多药结核的初步研究［J］. 中国新药杂志, 2008,17(6): 482-485.［18］ 彭丽,罗永艾,陈保文,黎友伦,沈小兵,王国治. 噬菌体对结核病模型豚鼠免疫功能的影响［J］.医药导报, 2006,25（8）:767-770.［19］ Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a sfety test of phage therapy［J］. Antimicrob Agents Chemother, 2005,49(7):2874-2878.［20］ 彭丽,罗永艾,沈小兵,王国治.分枝杆菌噬菌体生物学特性探讨［J］.微生物学免疫学进展,2005, 33(1): 19-23.［21］ Rybniker J, Kramme S, Small PL. Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria includingMycobacterium tuberculosis —application for identifyication and susceptibility testing［J］. J Med Microbiol, 2006,55(1):37-42.［22］ Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brüssow H.In vitroandin vivobacteriolytic activities ofEscherichia coliphages:implications for phage therapy［J］. Antimicrob Agents Chemother, 2004,48(7):2558-69.［23］ Platt R, Reynolds DL, Phillips GJ. Development of a novel method of lytic phage deliveryby use of a bacteriophage P22 site-specific recombination system［J］. FEMS Microbiol Let 2003,223(2):259-265.［24］ Barsom EK, Hatfull GF. Characterization of Mycobacterium smegmatis gene that confers resistance to phages L5 and D29 when overexpressed［J］. Mol Microbiol. 1996,21(1):159-170.［25］ Yacoby I, Shamis M, Bar H, Shabat D, Benhar I. Targeting antibacterial agentsby using drug-carrying filamentous bacteriophages［J］. Antimicrob Agents Chemother, 2006, 50(6):2087-2097.［26］ van Kessel JC, Hatfull GF. Recombineering inMycobacterium tuberculosis ［J］. Nat Methods, 2007,4(2):147-152.［27］ van Kessel JC, Hatfull GF. Efficient point mutagenesis in mycobacteria usingsingle-stranded DNA recombineering: characterization of antimycobacterial drug targets［J］. Mol Microbiol, 2008,67(5):1094-1107.［28］ van Kessel JC, Hatfull GF. Mycobacterial recombineering［J］. Methods Mol Biol, 2008,435:203-215.［29］ Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS. Use ofgenetically engineered phage to deliver antimicrobial agents to bacteria: an alternatevetherapy for treatment of bacterial infections［J］. Antimicrob Agents Chemother, 2003,47(4):1301-1307.［30］ Hagens S, Blsi U.Genetically modified filamentous phage as bactericidal agents: a pilotstudy［J］. Lett Appl Microbiol, 2003,37(4):318-323.［31］ Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential［J］. Trends Microbiol,1997,5(7):268-271.［32］ Projan S. Phage-inspired antibiotics?［J］. Nat Biotechnol, 2004,22(2):167-168.［33］ Liu J, Dehbi M, Moeck G, Arhin F, Bauda P, Bergeron D, Callejo M, Ferretti V,Ha N, Kwan T, McCarty J, Srikumar R, Williams D, Wu JJ, Gros P,Pelletier J, DuBow M. Antimicroial drug discovery through bacteriophage genomics［J］. Nat Biotechnol,2004,22(2):185-191.［34］ Rybniker J, Plum G, Robinson N, Small PL, Hartmann P. Identification of three cytotoxic early proteins of mycobacteriophage L5 leading to growth inhibition in Mycobacterium smegmatis［J］. Microbiology, 2008,154(8):2304-2314. ［35］ Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay JP. European regulatory conundrum of phage therapy［J］. Future Microbiol, 2007,2(5):485-491. |
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
